Last reviewed · How we verify
NCT03896256
Ketamine for Refractory Chronic Migraine: a Pilot Study
EARLY_PHASE1 trial testing ketamine infusion in Migraine Headache With Intractable Migraine in 6 participants. Completed in 1 January 2020.
1 January 2020
Quick facts
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 22 March 2019 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ketamine infusion — full drug profile →
Conditions studied
- Migraine Headache With Intractable Migraine — all drugs for Migraine Headache With Intractable Migraine →
Sponsor
Thomas Jefferson University
Who can join
18 and older, any sex, with Migraine Headache With Intractable Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually have tried and failed many medications and can cause severe disability to their lives. This study will evaluate ketamine prospectively when given to patients who have "failed" an initial inpatient treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.
Vekhova KA, Namiot ED, Jonsson J, Schiöth HB. · · 2025 · cited 17× · PMID 39428602 · DOI 10.1002/cpt.3478 -
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis.
Schwenk ES, Torjman MC, Moaddel R, Lovett J, et al · · 2021 · cited 11× · PMID 34125442 · DOI 10.1002/jcph.1920
Verify or expand the search:
- PubMed search for NCT03896256
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ketamine infusion
Trials testing the same drug.
- NCT01594047 — Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone · NA · completed
Other Thomas Jefferson University trials
Trials by the same sponsor.
- NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
- NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
- NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03896256 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
- Last refreshed: 11 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03896256.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing